Compare iShares Silver Trust (SLV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs BIO-TECHNE Corp — how do they compare? iShares Silver Trust trades at $53.12, while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while iShares Silver Trust pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | TECH | |
|---|---|---|
52-Week High | $105.57 | $72.12 |
52-Week Low | $33.32 | $43.31 |
Market Cap | — | $11.16B |
Sector | — | Health |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV, the iShares Silver Trust ETF, trades at $50.98 with a slight 0.39% daily gain. The technical outlook is bearish, with moving averages signaling strong selling pressure and oscillators neutral. Recent news highlights silver's dual role as a monetary and industrial metal, with supply deficits and geopolitical tensions influencing prices. Financial ratios are not applicable as SLV is a commodity trust tracking silver prices, not a company with earnings.
The outlook for SLV hinges on silver's price trajectory, supported by industrial demand and supply constraints but pressured by Fed policy and dollar strength. Risks include volatility from macroeconomic shifts and competition from other silver ETFs like SIVR. Analyst sentiment is mixed, with silver's performance lagging gold year-to-date, yet long-term demand drivers remain intact.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
